AAAAAA

   
Results: 1-25 | 26-50 | 51-56
Results: 1-25/56
SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OFA GLUCURONYL PRODRUG OF DOXORUBICIN, DOXORUBICIN AND ITS METABOLITES IN HUMAN LUNG-TISSUE
Authors: MURDTER TE SPERKER B BOSSLET K FRITZ P KROEMER HK
Citation: Te. Murdter et al., SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OFA GLUCURONYL PRODRUG OF DOXORUBICIN, DOXORUBICIN AND ITS METABOLITES IN HUMAN LUNG-TISSUE, Journal of chromatography B. Biomedical sciences and applications, 709(2), 1998, pp. 289-295
GUT WALL METABOLISM OF VERAPAMIL IN OLDER-PEOPLE - EFFECTS OF RIFAMPICIN-MEDIATED ENZYME-INDUCTION
Authors: FROMM MF DILGER K BUSSE D KROEMER HK EICHELBAUM M KLOTZ U
Citation: Mf. Fromm et al., GUT WALL METABOLISM OF VERAPAMIL IN OLDER-PEOPLE - EFFECTS OF RIFAMPICIN-MEDIATED ENZYME-INDUCTION, British journal of clinical pharmacology, 45(3), 1998, pp. 247-255
CLINICAL IMPLICATIONS OF DRUG-METABOLISM BY P450S AND OTHER ENZYMES
Authors: KROEMER HK
Citation: Hk. Kroemer, CLINICAL IMPLICATIONS OF DRUG-METABOLISM BY P450S AND OTHER ENZYMES, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 23-23
BETA-GLUCURONIDASE EXPRESSION, ACTIVITY, AND LOCALIZATION OF IN HUMANLUNG-CANCER - A BASE FOR DRUG TARGETING
Authors: MURDTER TE SPERKER B BACKMAN JT FRIEDEL G MCCLELLAN M FRITZ P BOSSLER K KROEMER HK
Citation: Te. Murdter et al., BETA-GLUCURONIDASE EXPRESSION, ACTIVITY, AND LOCALIZATION OF IN HUMANLUNG-CANCER - A BASE FOR DRUG TARGETING, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4518-4518
THAPSIGARGIN AND A23187-MEDIATED DOWN-REGULATION OF BETA-GLUCURONIDASE IN HEPG2 CELLS - CONSEQUENCES FOR DRUG TARGETING USING GLUCURONIDE PRODRUGS
Authors: SPERKER B TOMKIEWICZ C BAROUKI R KROEMER HK
Citation: B. Sperker et al., THAPSIGARGIN AND A23187-MEDIATED DOWN-REGULATION OF BETA-GLUCURONIDASE IN HEPG2 CELLS - CONSEQUENCES FOR DRUG TARGETING USING GLUCURONIDE PRODRUGS, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4519-4519
PHARMACOKINETIC INTERACTION BETWEEN DIGOXIN AND RIFAMPIN - THE ROLE OF P-GLYCOPROTEIN
Authors: GREINER B VONRICHTER O FRITZ P ZUNDLER J KREICHGAUER HP KROEMER HK EICHELBAUM M
Citation: B. Greiner et al., PHARMACOKINETIC INTERACTION BETWEEN DIGOXIN AND RIFAMPIN - THE ROLE OF P-GLYCOPROTEIN, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4729-4729
THE FATE OF NARINGIN, OF COUMARIN, AND OF NARINGIN PLUS COUMARIN IN MAN - WHERE OCCUR INTERACTIONS
Authors: GREINER B VONRICHTER O FRITZ P ZUNDLER J KREICHGAUER HP KROEMER HK EICHELBAUM M
Citation: B. Greiner et al., THE FATE OF NARINGIN, OF COUMARIN, AND OF NARINGIN PLUS COUMARIN IN MAN - WHERE OCCUR INTERACTIONS, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4731-4731
DRUG TARGETING BY GLUCURONIDE PRODRUGS - REGULATION OF THE BIOACTIVATING ENZYME BETA-GLUCURONIDASE IN THE HEPATOMA-CELL LINE HEPG2
Authors: SPERKER B TOMKIEWICZ C BAROUKI R KROEMER HK
Citation: B. Sperker et al., DRUG TARGETING BY GLUCURONIDE PRODRUGS - REGULATION OF THE BIOACTIVATING ENZYME BETA-GLUCURONIDASE IN THE HEPATOMA-CELL LINE HEPG2, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 62-62
MARKED DECREASE OF DIGOXIN BIOAVAILABILITY BY RIFAMPIN
Authors: GREINER B FRITZ P ZUNDLER J KREICHGAUER HP KROEMER HK EICHELBAUM M
Citation: B. Greiner et al., MARKED DECREASE OF DIGOXIN BIOAVAILABILITY BY RIFAMPIN, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 622-622
TUMORBIOLOGICAL CHARACTERISTICS OF NODE-POSITIVE BREAST CARCINOMAS - VARIABILITY AND SIGNIFICANCE FOR TREATMENT-RELATED OUTCOME
Authors: SIEGLE I BUSSE D OPALINSKA J KROEMER HK FRITZ P
Citation: I. Siegle et al., TUMORBIOLOGICAL CHARACTERISTICS OF NODE-POSITIVE BREAST CARCINOMAS - VARIABILITY AND SIGNIFICANCE FOR TREATMENT-RELATED OUTCOME, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 656-656
VARIABILITY OF CYCLOPHOSPHAMIDE DISPOSITION IN BRONCHIAL-CARCINOMA
Authors: BOHNENSTENGEL F FRIEDEL G MCCLELLAN M FRITZ P LINDER A TOOMES H DIERKESMANN R KROEMER HK
Citation: F. Bohnenstengel et al., VARIABILITY OF CYCLOPHOSPHAMIDE DISPOSITION IN BRONCHIAL-CARCINOMA, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 664-664
NON ANTI-APOPTOTIC FUNCTION OF BCR-ABL AGAINST GAMMA-IRRADIATION OR DOXORUBICIN IN A HUMAN MEGACARYOCYTIC CELL-LINE
Authors: GOTZ A JONULEIT T KROEMER HK AULITZKY WE
Citation: A. Gotz et al., NON ANTI-APOPTOTIC FUNCTION OF BCR-ABL AGAINST GAMMA-IRRADIATION OR DOXORUBICIN IN A HUMAN MEGACARYOCYTIC CELL-LINE, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 670-670
QUANTIFICATION OF TETRAHYDROTHIOPHENE FOLLOWING INCUBATION OF BUSULFAN WITH HUMAN LIVER CYTOSOL
Authors: RITTER C BOHNENSTENGEL F HOFMANN U KROEMER HK
Citation: C. Ritter et al., QUANTIFICATION OF TETRAHYDROTHIOPHENE FOLLOWING INCUBATION OF BUSULFAN WITH HUMAN LIVER CYTOSOL, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 680-680
ELUCIDATION OF THE MECHANISM ENABLING TUMOR SELECTIVE PRODRUG MONOTHERAPY
Authors: BOSSLET K STRAUB R BLUMRICH M CZECH J GERKEN M SPERKER B KROEMER HK GESSON JP KOCH M MONNERET C
Citation: K. Bosslet et al., ELUCIDATION OF THE MECHANISM ENABLING TUMOR SELECTIVE PRODRUG MONOTHERAPY, Cancer research, 58(6), 1998, pp. 1195-1201
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF ACROLEIN AS A MARKER FOR CYCLOPHOSPHAMIDE BIOACTIVATION IN HUMAN LIVER-MICROSOMES
Authors: BOHNENSTENGEL F EICHELBAUM M GOLBS E KROEMER HK
Citation: F. Bohnenstengel et al., HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF ACROLEIN AS A MARKER FOR CYCLOPHOSPHAMIDE BIOACTIVATION IN HUMAN LIVER-MICROSOMES, Journal of chromatography B. Biomedical sciences and applications, 692(1), 1997, pp. 163-168
ANALYSIS OF CYP2D6 EXPRESSION IN HUMAN LUNG - IMPLICATIONS FOR THE ASSOCIATION BETWEEN CYP2D6 ACTIVITY AND SUSCEPTIBILITY TO LUNG-CANCER
Authors: KIVISTO KT GRIESE KU STUVEN T FRITZ P FRIEDEL G KROEMER HK ZANGER UM
Citation: Kt. Kivisto et al., ANALYSIS OF CYP2D6 EXPRESSION IN HUMAN LUNG - IMPLICATIONS FOR THE ASSOCIATION BETWEEN CYP2D6 ACTIVITY AND SUSCEPTIBILITY TO LUNG-CANCER, Pharmacogenetics, 7(4), 1997, pp. 295-302
DOSE-ESCALATION OF CYCLOPHOSPHAMIDE IN PATIENTS WITH BREAST-CANCER - CONSEQUENCES FOR PHARMACOKINETICS AND METABOLISM
Authors: BUSSE D BUSCH FW BOHNENSTENGEL F EICHELBAUM M FISCHER P OPALINSKA J SCHUMACHER K SCHWEIZER E KROEMER HK
Citation: D. Busse et al., DOSE-ESCALATION OF CYCLOPHOSPHAMIDE IN PATIENTS WITH BREAST-CANCER - CONSEQUENCES FOR PHARMACOKINETICS AND METABOLISM, Journal of clinical oncology, 15(5), 1997, pp. 1885-1896
THE ROLE OF BETA-GLUCURONIDASE IN DRUG DISPOSITION AND DRUG TARGETINGIN HUMANS
Authors: SPERKER B BACKMAN JT KROEMER HK
Citation: B. Sperker et al., THE ROLE OF BETA-GLUCURONIDASE IN DRUG DISPOSITION AND DRUG TARGETINGIN HUMANS, Clinical pharmacokinetics, 33(1), 1997, pp. 18-31
IMPACT OF P450 GENETIC-POLYMORPHISM ON THE FIRST-PASS EXTRACTION OF CARDIOVASCULAR AND NEUROACTIVE DRUGS
Authors: FROMM MF KROEMER HK EICHELBAUM M
Citation: Mf. Fromm et al., IMPACT OF P450 GENETIC-POLYMORPHISM ON THE FIRST-PASS EXTRACTION OF CARDIOVASCULAR AND NEUROACTIVE DRUGS, Advanced drug delivery reviews, 27(2-3), 1997, pp. 171-199
USE OF PROBE DRUGS AS PREDICTORS OF DRUG-METABOLISM IN HUMANS
Authors: KIVISTO KT KROEMER HK
Citation: Kt. Kivisto et Hk. Kroemer, USE OF PROBE DRUGS AS PREDICTORS OF DRUG-METABOLISM IN HUMANS, Journal of clinical pharmacology, 37(1), 1997, pp. 40-48
IN-VIVO ASSESSMENT OF INTESTINAL DRUG-METABOLISM - REPLY
Authors: HOLTBECKER N FROMM MF KROEMER HK OHNHAUS EE HEIDEMANN H
Citation: N. Holtbecker et al., IN-VIVO ASSESSMENT OF INTESTINAL DRUG-METABOLISM - REPLY, Drug metabolism and disposition, 25(9), 1997, pp. 1110-1111
DIFFERENT APPLICATION SCHEDULES OF HIGH-DOSE CYCLOPHOSPHAMIDE - INFLUENCE ON KINETICS AND METABOLISM
Authors: BUSSE D BUSCH FW BOHNENSTENGEL F EICHELBAUM M FISCHER P SCHUMACHER K SCHWEIZER E KROEMER HK
Citation: D. Busse et al., DIFFERENT APPLICATION SCHEDULES OF HIGH-DOSE CYCLOPHOSPHAMIDE - INFLUENCE ON KINETICS AND METABOLISM, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 449-449
BIOACTIVATION OF A GLUCURONYL-SPACER-DOXORUBICIN PRODRUG BY BETA-GLUCURONIDASE - A STUDY USING THE HUMAN LUNG PERFUSION MODEL
Authors: MURDTER TE SPERKER B FRIEDEL G LINDER A KIVISTO KT MCCLELLAN M FRITZ P BOSSLET K KROEMER HK
Citation: Te. Murdter et al., BIOACTIVATION OF A GLUCURONYL-SPACER-DOXORUBICIN PRODRUG BY BETA-GLUCURONIDASE - A STUDY USING THE HUMAN LUNG PERFUSION MODEL, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 455-455
BIOACTIVATION OF CYCLOPHOSPHAMIDE IN HUMAN LIVER-MICROSOMES - PREDICTIVE VALUE OF IN-VITRO DATA
Authors: BOHNENSTENGEL F BUSSE D EICHELBAUM M KROEMER HK
Citation: F. Bohnenstengel et al., BIOACTIVATION OF CYCLOPHOSPHAMIDE IN HUMAN LIVER-MICROSOMES - PREDICTIVE VALUE OF IN-VITRO DATA, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 461-461
INTERINDIVIDUAL VARIABILITY IN EXPRESSION AND ACTIVITY OF HUMAN BETA-GLUCURONIDASE IN LIVER AND KIDNEY - CONSEQUENCES FOR DRUG-METABOLISM
Authors: SPERKER B MURDTER TE SCHICK M ECKHARDT K BOSSLET K KROEMER HK
Citation: B. Sperker et al., INTERINDIVIDUAL VARIABILITY IN EXPRESSION AND ACTIVITY OF HUMAN BETA-GLUCURONIDASE IN LIVER AND KIDNEY - CONSEQUENCES FOR DRUG-METABOLISM, The Journal of pharmacology and experimental therapeutics, 281(2), 1997, pp. 914-920
Risultati: 1-25 | 26-50 | 51-56